Sinovac Biotech (NASDAQ:SVA) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Thursday.

Sinovac Biotech (NASDAQ SVA) traded down $0.09 during mid-day trading on Thursday, hitting $7.71. The company’s stock had a trading volume of 378,633 shares, compared to its average volume of 139,885. Sinovac Biotech has a 1 year low of $4.60 and a 1 year high of $7.98.

Several hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in shares of Sinovac Biotech by 8.0% during the 2nd quarter. Renaissance Technologies LLC now owns 1,814,300 shares of the biopharmaceutical company’s stock worth $12,247,000 after acquiring an additional 134,810 shares during the period. GLG Partners LP grew its holdings in shares of Sinovac Biotech by 144.8% during the 2nd quarter. GLG Partners LP now owns 282,611 shares of the biopharmaceutical company’s stock worth $1,908,000 after acquiring an additional 167,165 shares during the period. State Street Corp grew its holdings in shares of Sinovac Biotech by 18.5% during the 2nd quarter. State Street Corp now owns 49,281 shares of the biopharmaceutical company’s stock worth $333,000 after acquiring an additional 7,711 shares during the period. Citadel Advisors LLC grew its holdings in shares of Sinovac Biotech by 189.8% during the 3rd quarter. Citadel Advisors LLC now owns 34,193 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 22,393 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Sinovac Biotech during the 3rd quarter worth approximately $163,000. Hedge funds and other institutional investors own 31.80% of the company’s stock.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/sinovac-biotech-sva-downgraded-by-bidaskclub-to-buy.html.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.